BiotechTube

EC-MPS

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Conditions

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Trial Timeline

Apr 1, 2003 → —

NCT ID
NCT00238446

About EC-MPS

EC-MPS is a phase 3 stage product being developed by Novartis for Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS. The current trial status is completed. This product is registered under clinical trial identifier NCT00238446. Target conditions include Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS.

What happened to similar drugs?

18 of 20 similar drugs in Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS were approved

Approved (18) Terminated (1) Active (2)
✅ATG-FAstellas PharmaApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅BenralizumabAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Imipenem + ImipenemMerckApproved
✅Cyclosporine - cyclosporine microemulsionNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00238446Phase 3Completed

Competing Products

20 competing products in Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29